Trials / Recruiting
RecruitingNCT05056857
Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen
Neutrophil Functions in Breast Cancer
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 290 (estimated)
- Sponsor
- M.D. Anderson Cancer Center · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This study examines the long-term effects of tamoxifen (TAM) treatment on excessive production of neutrophil extracellular traps (NET) and their impact on breast cancer and side effects. NET are produced by the body to fight infections but have also been linked to side effects caused by the body's immune system. Treatment with tamoxifen increases the production of NETs. This study may help researchers determine if the increased number of NETs in the body has a damaging effect in breast cancer.
Detailed description
PRIMARY OBJECTIVE: I. To examine the effect of long-term tamoxifen (TAM) treatment on excessive NET formation in breast cancer patients. SECONDARY OBJECTIVES: I. To understand the molecular mechanisms of tamoxifen-induced NET formation in breast cancer patients by examining the effect of long-term TAM treatment on the NET-induced factors. II. To correlate the extend of NET formation with clinical data on tamoxifen resistance, drug side-effects, cancer metastasis and comorbidities. EXPLORATORY OBJECTIVE: I. To explore the association between the extent of NET formation and clinical data for breast cancer patients treated with TAM in combination with other drugs. OUTLINE: Patients undergo collection of blood samples and their medical charts are reviewed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Biospecimen Collection | Undergo collection of blood sample |
| OTHER | Electronic Health Record Review | Medical charts are reviewed |
Timeline
- Start date
- 2021-10-01
- Primary completion
- 2026-10-31
- Completion
- 2026-10-31
- First posted
- 2021-09-27
- Last updated
- 2025-12-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05056857. Inclusion in this directory is not an endorsement.